Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Baudin

Showing results (141-150 of 241) with videos related to

Pageof 25
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trialMichel Ducreux, Laetitia Dahan, Denis Smith, et al.
Thyroid : Official Journal of the American Thyroid Association|October 29, 2025
Validation of the International Medullary Thyroid Carcinoma Grading System in Patients with Distant MetastasesTommaso Porcelli, Sophie Moog, Mohamed-Amine Bani, et al.
Thyroid : Official Journal of the American Thyroid Association|September 12, 2023
Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case ReportsSophie Moog, Livia Lamartina, Mohamed-Amine Bani, et al.
The Journal of Clinical Endocrinology and Metabolism|August 30, 2007
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levelsAnne Laure Giraudet, Daniel Vanel, Sophie Leboulleux, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 17, 2020
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practiceVikas Prasad, Raj Srirajaskanthan, Christos Toumpanakis, et al.
European Journal of Endocrinology|January 16, 2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF networkMarie-Hélène Massicotte, Maryse Brassard, Médéric Claude-Desroches, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETESégolène Hescot, Véronique Debien, Julien Hadoux, et al.
European Journal of Endocrinology|December 23, 2011
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinomaAlfredo Berruti, Paola Sperone, Anna Ferrero, et al.
Presse Medicale (Paris, France : 1983)|May 27, 2014
[Malignant insulinoma: recommendations for workup and treatment]Eric Baudin, Philippe Caron, Catherine Lombard-Bohas, et al.
Lancet (London, England)|November 29, 2011
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyMarianne E Pavel, John D Hainsworth, Eric Baudin, et al.
Pageof 25

Showing results (141-150 of 241) with videos related to

Sort By:
Pageof 25
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trialMichel Ducreux, Laetitia Dahan, Denis Smith, et al.
Thyroid : Official Journal of the American Thyroid Association|October 29, 2025
Validation of the International Medullary Thyroid Carcinoma Grading System in Patients with Distant MetastasesTommaso Porcelli, Sophie Moog, Mohamed-Amine Bani, et al.
Thyroid : Official Journal of the American Thyroid Association|September 12, 2023
Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case ReportsSophie Moog, Livia Lamartina, Mohamed-Amine Bani, et al.
The Journal of Clinical Endocrinology and Metabolism|August 30, 2007
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levelsAnne Laure Giraudet, Daniel Vanel, Sophie Leboulleux, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 17, 2020
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practiceVikas Prasad, Raj Srirajaskanthan, Christos Toumpanakis, et al.
European Journal of Endocrinology|January 16, 2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF networkMarie-Hélène Massicotte, Maryse Brassard, Médéric Claude-Desroches, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETESégolène Hescot, Véronique Debien, Julien Hadoux, et al.
European Journal of Endocrinology|December 23, 2011
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinomaAlfredo Berruti, Paola Sperone, Anna Ferrero, et al.
Presse Medicale (Paris, France : 1983)|May 27, 2014
[Malignant insulinoma: recommendations for workup and treatment]Eric Baudin, Philippe Caron, Catherine Lombard-Bohas, et al.
Lancet (London, England)|November 29, 2011
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyMarianne E Pavel, John D Hainsworth, Eric Baudin, et al.
Pageof 25